Altimmune, Inc. (ALT)
3.515
-0.10
(-2.63%)
USD |
NASDAQ |
Jan 02, 16:00
3.51
0.00 (0.00%)
After-Hours: 17:25
Altimmune Research and Development Expense (TTM): 67.72M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Viking Therapeutics, Inc. | 222.48M |
| Amgen, Inc. | 6.828B |
| Rhythm Pharmaceuticals, Inc. | 165.86M |
| Terns Pharmaceuticals, Inc. | 76.99M |
| X4 Pharmaceuticals, Inc. | 75.34M |